Zavegepant, sold under the brand name Zavzpret, is a medication used for the treatment of migraine. Zavegepant is a calcitonin gene-related peptide receptor antagonist. It is sprayed into the nose. It is sold by Pfizer.

The most common adverse reactions include taste disorders, nausea, nasal discomfort, and vomiting.

Zavegepant was approved for medical use in the United States in March 2023.

Medical uses

Zavegepant is indicated for the acute treatment of migraine with or without aura in adults.

Further reading

  • Croop R, Madonia J, Stock DA, Thiry A, Forshaw M, Murphy A, Coric V, Lipton RB (October 2022). . Headache. 62 (9): 1153–1163. doi:. PMC . PMID .
  • Noor N, Angelette A, Lawson A, Patel A, Urits I, Viswanath O, et al. (2022). . Health Psychology Research. 10 (3) 35506. doi: (inactive 1 July 2025). PMC . PMID .{{cite journal}}: CS1 maint: DOI inactive as of July 2025 (link)
  • Scuteri D, Tarsitano A, Tonin P, Bagetta G, Corasaniti MT (November 2022). "Focus on zavegepant: the first intranasal third-generation gepant". Pain Management. 12 (8): 879–885. doi:. PMID . S2CID .

External links

  • Clinical trial number for "Randomized Trial in Adult Subjects With Acute Migraines" at ClinicalTrials.gov
  • Clinical trial number for "Acute Treatment Trial in Adult Subjects With Migraines" at ClinicalTrials.gov